These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1982 related items for PubMed ID: 18845169

  • 1. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 2. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells.
    Lee SY, Rhee YH, Jeong SJ, Lee HJ, Lee HJ, Jung MH, Kim SH, Lee EO, Ahn KS, Ahn KS, Kim SH.
    Environ Toxicol; 2011 Aug 21; 26(4):424-31. PubMed ID: 20196146
    [Abstract] [Full Text] [Related]

  • 3. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
    Choi JS, Kang NS, Min YK, Kim SH.
    Phytother Res; 2010 Jul 21; 24(7):1042-6. PubMed ID: 19960428
    [Abstract] [Full Text] [Related]

  • 4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX, Yang XH.
    Yao Xue Xue Bao; 2008 May 21; 43(5):461-6. PubMed ID: 18717331
    [Abstract] [Full Text] [Related]

  • 5. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening.
    Wesolowska O, Paprocka M, Kozlak J, Motohashi N, Dus D, Michalak K.
    Anticancer Res; 2005 May 21; 25(1A):383-9. PubMed ID: 15816562
    [Abstract] [Full Text] [Related]

  • 6. Anticancer effects of a specific mixture of nutrients in the multidrug-resistant human uterine sarcoma MES-SA/Dx5 and the drug-sensitive MES-SA cell lines.
    Roomi MW, Kalinovsky T, Roomi NW, Rath M, Niedzwiecki A.
    Oncol Rep; 2012 Jan 21; 27(1):17-27. PubMed ID: 21947138
    [Abstract] [Full Text] [Related]

  • 7. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.
    Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E.
    Oncol Rep; 2008 Oct 21; 20(4):731-5. PubMed ID: 18813811
    [Abstract] [Full Text] [Related]

  • 8. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein.
    Kim YK, Song YJ, Seo DW, Kang DW, Lee HY, Rhee DK, Han JW, Ahn CM, Lee S, Kim SN.
    Biochem Biophys Res Commun; 2007 Mar 30; 355(1):136-42. PubMed ID: 17286965
    [Abstract] [Full Text] [Related]

  • 9. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
    Traunecker HC, Stevens MC, Kerr DJ, Ferry DR.
    Br J Cancer; 1999 Nov 30; 81(6):942-51. PubMed ID: 10576649
    [Abstract] [Full Text] [Related]

  • 10. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 30; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 11. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
    Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F.
    J Biol Regul Homeost Agents; 2010 Nov 30; 24(2):197-205. PubMed ID: 20487633
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Nov 30; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 13. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 30; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 14. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2002 May 30; 49(5):391-7. PubMed ID: 11976833
    [Abstract] [Full Text] [Related]

  • 15. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
    Wang E, Lee MD, Dunn KW.
    J Cell Physiol; 2000 Aug 30; 184(2):263-74. PubMed ID: 10867652
    [Abstract] [Full Text] [Related]

  • 16. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
    Shi R, Li W, Zhang X, Zhang Y, Peng H, Xie Y, Fan D, Liu R, Liu X, Xiong D.
    Eur J Pharmacol; 2011 Nov 01; 669(1-3):38-44. PubMed ID: 21871878
    [Abstract] [Full Text] [Related]

  • 17. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS, He L.
    J Pharm Pharmacol; 2007 Jul 01; 59(7):1011-5. PubMed ID: 17637197
    [Abstract] [Full Text] [Related]

  • 18. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD.
    Cancer Res; 2000 Jun 01; 60(11):2964-72. PubMed ID: 10850444
    [Abstract] [Full Text] [Related]

  • 19. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
    Chen F, Wang T, Wang J, Wang ZQ, Qian M.
    Acta Pharmacol Sin; 2008 Apr 01; 29(4):458-64. PubMed ID: 18358092
    [Abstract] [Full Text] [Related]

  • 20. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D, Fang L, Zhu Q, Hu Y, He Q, Yang B.
    Pharmazie; 2008 Jul 01; 63(7):528-33. PubMed ID: 18717489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 100.